title: Quetiapine dosage across diagnostic categories.
abstract: OBJECTIVE
  The aim of the current study was to evaluate quetiapine doses used across diagnosis categories in a sample of psychiatric inpatients.
  
  
  METHODS
  Discharge letters of all adult inpatients who had received quetiapine between 1999 and 2005 were retrospectively reviewed. Logistic regressions were carried-out to assess links between quetiapine discharge dosage (> or =800 mg/day vs. <800 mg/day), diagnostic categories, substance abuse or dependence, benzodiazepine discharge doses, age and sex.
  
  
  RESULTS
  The data of 231 patients were included. Five hundred and for discharge documents were analyzed: 113 for psychotic disorders, 190 for personality disorders, 134 for bipolar and schizoaffective bipolar disorders, 29 for unipolar depression or anxiety disorders, and 35 for mental retardation. Considering psychotic disorders as a reference group, patients with personality disorders were statistically significantly less likely to be in the high quetiapine dosage group at discharge (P = 0.007, OR = 0.1 and CI [0.03; 0.6]).
  
  
  CONCLUSIONS
  Quetiapine seems to be used in a variety of clinical situations, with a wide range of doses and a lower dosage in patients treated for personality disorders.
authors.affiliation: Division of Substance Abuse, Geneva University Hospitals, Rue Verte 2, 1205 Geneva, Switzerland. yasser.khazaal@hcuge.ch
authors.forename: Yasser
authors.initials: Y
authors.lastname: Khazaal
authors.forename: Anne
authors.initials: A
authors.lastname: Chatton
authors.forename: Riaz
authors.initials: R
authors.lastname: Khan
authors.forename: Daniele
authors.initials: D
authors.lastname: Zullino
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy; D001569:Benzodiazepines / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy; D003430:Cross-Sectional Studies; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy; D003987:Dibenzothiazepines / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D010351:Patient Discharge; D010359:Patient Readmission; D010554:Personality Disorders / Q000175:diagnosis / Q000188:drug therapy; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy; D000069348:Quetiapine Fumarate; D012189:Retrospective Studies
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate